scPharmaceuticals to Participate in Two Upcoming Investor Conferences
Get Alerts SCPH Hot Sheet
Join SI Premium – FREE
BURLINGTON, Mass.--(BUSINESS WIRE)-- scPharmaceuticals Inc. (Nasdaq: SCPH), a pharmaceutical company focused on developing and commercializing products that have the potential to optimize the delivery of infused therapies, advance patient care, and reduce healthcare costs, today announced that management will participate in two upcoming investor conferences.
John Tucker, Chief Executive Officer, is scheduled to present at the virtual H.C. Wainwright 22nd Annual Global Investment Conference on Wednesday, September 16 at 1:00pm EDT.
Investors may register for the conference here.
Mr. Tucker is also scheduled to participate in the Cantor Fitzgerald Virtual Global Healthcare Conference on Thursday, September 17 at 12:00pm EDT.
A live webcast of both sessions can be accessed under “News & Events” in the Investor Relations section of the Company’s website, www.scpharmaceuticals.com.
About scPharmaceuticals
scPharmaceuticals is a pharmaceutical company focused on developing and commercializing products that are designed to reduce healthcare costs and improve health outcomes. The Company develops, internally and through strategic partnerships, innovative products and solutions that aim to expand and advance the outpatient care of select acute conditions. The Company’s lead programs focus on the subcutaneous, self-administration of IV-strength treatments in heart failure and infectious disease. scPharmaceuticals is headquartered in Burlington, MA. For more information, please visit www.scPharmaceuticals.com.
View source version on businesswire.com: https://www.businesswire.com/news/home/20200903005278/en/
Katherine Taudvin
scPharmaceuticals Inc., 781-301-6706
[email protected]
Investors:
Hans Vitzthum
LifeSci Advisors, 617-430-7578
[email protected]
Media:
Kate Coyle
ICR Inc., 203-682-8210
[email protected]
Source: scPharmaceuticals Inc.
Serious News for Serious Traders! Try StreetInsider.com Premium Free!
You May Also Be Interested In
- FairJourney Bio Delivers Antibody Engineering for Novel Tumor-Conditional IL-12 Therapeutic Approach That Unlocks the Potential of Localized Cytokine Activation
- ATRenew Inc. Reports Unaudited Second Quarter 2026 Financial Results
- EHang Partners with CSCEC Sixth Engineering Bureau on Low-Altitude Infrastructure, with Hainan Lingao Corridor Project Underway
Create E-mail Alert Related Categories
Business Wire, Press ReleasesRelated Entities
Cantor Fitzgerald, H.C. WainwrightSign up for StreetInsider Free!
Receive full access to all new and archived articles, unlimited portfolio tracking, e-mail alerts, custom newswires and RSS feeds - and more!



Tweet
Share